Access

Genomics should be available to the many, not the few. It has the power to save lives and vastly improve the human condition. As the leader in genomics, we have the obligation to drive down the cost of sequencing, expand access to diagnostics technology, and increase the diversity of genomics data to realize health equity for billions of people around the world.

Videos from this campaign

Stephanie Lheureux, MD, PhD,Princess Margaret Cancer Centre (PMCC).
Illumina Booth at UK Festival of Genomics & Biodata

Content from this campaign

Health & Healthcare

Illumina Launches Research Test Codeveloped With Merck To Unlock Deeper Insights Into the Tumor Genome
llumina, a global leader in DNA sequencing and array-based technologies, today announced the launch of a research test, codeveloped with Merck (known as MSD outside the United States and Canada).

Health & Healthcare

AI Drives Data Insights for Doctors and Their Patients
Dr. Lina Basel-Salmon has been treating rare disease patients at Schneider Children’s Medical Center of Israel and Beilinson Hospital at the Rabin Medical Center for 22 years.

Health & Healthcare

“All Patients Should Have Their Tumor Sequenced At Least Once”
This year’s American Society of Clinical Oncology (ASCO) 2022 Annual Meeting took place in person at the Hyatt Regency in Chicago and online, June 3-7.

Health & Healthcare

Exome Sequencing Reveals Misdiagnoses in Epidermolysis Bullosa Patients
DEBRA International has a simple mission: help patients and families dealing with epidermolysis bullosa (EB), a rare genetic condition that affects collagen production, making skin and other membranes quite fragile.

Health & Healthcare

PRECISE-ILLUMINA Partnership Agreement
Precision Health Research, Singapore (PRECISE), the central entity implementing Singapore’s National Precision Medicine (NPM) strategy, and Illumina, Inc (Illumina), a leader in genomics technology, announced today a strategic partnership to sequence and analyse 100,000 Singaporean whole genomes (SG100K), to create for the first time, Southeast Asia’s most comprehensive consented population study.

Health & Healthcare

Illumina Introduces New Pan-Cancer Companion Diagnostic to Match Patients With Rare Genetic Mutations to Targeted Therapy
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the addition of a companion diagnostic (CDx) indication to its CE-marked in vitro diagnostic TruSight™ Oncology (TSO) Comprehensive (EU) test. This single test kit, recently launched across Europe, assesses multiple tumor genes and biomarkers to reveal the specific molecular profile of a patient's cancer.

Health & Healthcare

Illumina and Allegheny Health Network to Assess In-House Comprehensive Cancer Genomic Profiling to Enhance Patient Care
Illumina, Inc. (NASDAQ: ILMN) a global leader in DNA sequencing and array-based technologies, and Allegheny Health Network (AHN), an integrated health system serving the Western Pennsylvania area, today announced a collaboration to evaluate the impact of in-house comprehensive genomic profiling (CGP) to enhance patient care.

Health & Healthcare

Illumina and Deerfield Management Partner to Accelerate Drug Development
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Deerfield Management, a healthcare investment management firm, today announced a five-year partnership to apply a genetic-led approach to the discovery and development of novel therapies for diseases with unmet medical needs.

Health & Healthcare

Illumina Partners With Allelica, Inc.
Customers and our partners represent the heartbeat of Illumina. They help us advance our mission to improve human health through unlocking the power of the genome.

Health & Healthcare

Illumina Announces Long-Term Strategic Partnership with Janssen
I’m proud to announce that today, during the World CDx Summit in London, Illumina, Inc. announced a long-term strategic collaboration with Janssen Biotech, Inc. (Janssen) to accelerate the development of precision medicines.
Illumina logo

More from Illumina

  1. Community
    By sharing our time, talent, and technology, we aim to inspire, support, and empower our communities, our employees, and the next generation.

  2. Access
    Genomics should be available to the many, not the few. It has the power to save lives and vastly improve the human condition. As the leader in...

  3. Environment
    We are committed to integrating environmental stewardship into the way we operate. We recognize the importance of the environment in creating a...

  4. Business
    At Illumina, the faster we can innovate, the more lives we can help save. As a genomics pioneer, we have proven through focused and continued...

  5. Operating Responsibly
    Our role as a genomics pioneer brings with it the responsibility to enable innovation for good, ensuring that the technology we create and the data we...

  6. People
    Harnessing the world’s best talent and giving them the opportunity to thrive allows us to make world-changing leaps in human health and beyond. Our...